Getting prescribed TRT: what the process actually involves

What did @kmartfit actually say?

The creator laid out a specific pitch: find an online TRT clinic, get a blood test, and if your total testosterone comes in under 550 ng/dL, you'll "most likely" get prescribed injections. The all-in cost he quoted was $169 a month, covering doctor visits, quarterly blood work, and home delivery. He ended with a lead-gen call to action, asking viewers to comment "TRT" for his referral resources. This is essentially an advertisement structured as health advice.

To be clear about what he did not say: he never mentioned symptoms, never discussed the difference between primary and secondary hypogonadism, and never acknowledged that a single lab number does not a diagnosis make. The framing is transactional, not clinical.

Does the science back this up?

The 550 ng/dL threshold he named is not a recognized clinical cutoff, and that matters. Most major guidelines draw the line considerably lower.

The American Urological Association and the Endocrine Society both define biochemical hypogonadism at consistently low total testosterone, generally below 300 ng/dL, confirmed on at least two separate morning draws (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism). The AUA's 2018 guidelines specifically state that testosterone therapy should not be initiated based on a single measurement.

A 550 ng/dL result sits squarely in the normal range by every major clinical standard currently in use. Treating someone at that level is not evidence-based practice. A 2020 review in JAMA Internal Medicine (Nguyen et al.) found that prescribing rates for TRT have risen sharply even among men without a confirmed diagnosis, which is exactly the pattern this kind of content accelerates.

What did they get wrong (or right)?

Wrong, and pretty significantly: the 550 ng/dL cutoff. This is the most consequential claim in the video. Framing it as a likely prescription threshold misleads viewers into thinking they have a clinical condition when they may be entirely within the normal range. That is not a minor distinction. Long-term testosterone therapy suppresses endogenous production and carries real risks including erythrocytosis, infertility, and cardiovascular changes (Xu et al., 2013, BMJ).

What he got right, partially: telehealth TRT platforms do exist and are legal. Quarterly blood work monitoring is genuinely standard of care. Home delivery of compounded or commercial testosterone is a real option in many states. The logistics he described are not fabricated, they are just stripped of the clinical gatekeeping those logistics are supposed to include.

• The 550 threshold: not a real clinical cutoff. Inaccurate.
• Quarterly blood monitoring included: consistent with standard practice. Accurate.
• Home delivery of prescribed testosterone: legal and real in most states. Accurate.
• "Most likely will prescribe you": irresponsible framing for a 550 result. Misleading.

What should you actually know?

If you are considering TRT, the number that matters is not just the number. Symptoms matter. Morning fasting draws matter. Confirmation on a second test matters. Your LH, FSH, and SHBG levels matter because they tell you why your testosterone is low, not just that it is.

The Endocrine Society recommends TRT only for men with both consistently low testosterone and symptoms of hypogonadism: reduced libido, fatigue, loss of muscle mass, depressed mood. One lab result from an online clinic is a starting point, not a prescription pad.

The $169/month price point is real for some telehealth platforms, but costs vary significantly depending on whether you are receiving compounded testosterone cypionate or a brand-name product. These are not clinically equivalent under current FDA guidance, and that distinction should be part of any informed consent conversation.

A legitimate TRT evaluation includes a thorough symptom history, two morning testosterone draws, and a workup that rules out reversible causes like obesity, sleep apnea, or medication side effects before hormones are prescribed (Mulhall et al., 2018, Journal of Urology).